A Second-Generation Oral SARS-CoV‑2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Deriving general structure–activity/selectivity relationship patterns for different subfamilies of cyclin-dependent kinase inhibitors using machine

One Chiral Fingerprint To Find Them All Markus Orsi & Jean-Louis Reymond. J. Cheminform.,

Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the

The First ATP Competitive Type-III c-MET Inhibitor? In this paper, the target was c-MET,

Modelling P-gp efflux may help us design better molecules   In order to treat

Where Old Meets New: Advancements in AlphaFold with Some Help From Boltzmann   With

The Importance of Tracking "Missing' Metabolites: How and Why? Throughout the course of in-vivo

Machine Learning Strategies for Reaction Development: Toward the Low-Data Limit This useful perspective article

Discovery of an Oral, Beyond-Rule-of-Five Mcl‐1 Protein−Protein Interaction Modulator with the Potential of Treating